Lipotoxicity-related cardiac abnormalities can be reversed by PPAR g agonist therapy in type 2 diabetes patients.
ID
Bron
Verkorte titel
Aandoening
Type 2 Diabetes Mellitus, Heart Disease
Ondersteuning
De Boelelaan 1117
1081 HV Amsterdam
The Netherlands
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Changes in cardiac function and metabolism following treatment with PPARg agonist versus current state of the art therapy, metformin.
Achtergrond van het onderzoek
Background/hypothesis:
Patients with type 2 diabetes mellitus (DM2) have a considerably higher risk to develop cardiac disease with a poorer outcome. Ectopic triglyceride (TG) accumulation underlies diabetic cardiomyopathy. These cardiac abnormalities can be reversed by lowering myocardial TG using a peroxisome proliferator-activated receptor (PPAR) g agonist. Metformin, the present gold standard treatment for type 2 diabetes, might also have cardioprotective properties due to its recently proposed mechanism of action.
Doel van het onderzoek
Lipotoxicity-related cardiac abnormalities can be reversed by PPAR g agonist therapy in type 2 diabetes patients.
Onderzoeksopzet
N/A
Onderzoeksproduct en/of interventie
80 subjects on monotherapy sulfanylurea for at least 10 weeks will be enrolled. Following, participants will be randomised to Metformin or Pioglitazone for 24 weeks.
Group 1: Metformin;
Group 2: Pioglitazone
10 healthy subject will only undergo baseline measurements.
Publiek
De Boelelaan 1117
L.J. Rijzewijk
De Boelelaan 1117
Amsterdam 1081 HV
The Netherlands
+31 (0)20 4442758
Wetenschappelijk
De Boelelaan 1117
L.J. Rijzewijk
De Boelelaan 1117
Amsterdam 1081 HV
The Netherlands
+31 (0)20 4442758
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
Type 2 Diabetes PatientsMales, 45-65 years, DM2 (diagnosed according to WHO criteria, treated by monotherapy of sulfanylurea (i.e. unchanged during >30 days prior to inclusion).
At least three month stable HbA1c (<8.5%) under this therapy.
Sitting blood pressure <150/85 mmHg with or without antihypertensive drugs, BMI<32 kg/m2.Healthy volunteers, Healthy male subjects, 45-65 years, Normal sitting blood pressure <150/85 mmHg, BMI<32 kg/m2. Normal glucose tolerance as assessed by 75-g oral glucose tolerance test.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
Type 2 Diabetes Patients, CAD, Active malignant disease, Impaired renal function (serum creatinine > 176 mmol/L), Weight >/= 45 kg (because of 11C-palmitate tracer), Anti-coagulant therapy, Severe
obstructive lung disease; hereditary lipoprotein disease, Impaired hepatic function (defined as ALT > 3 ULN) or a history of liver disease, Inability to understand study information, inability / unwillingness to sign informed consent, Substance abuse, Familial polyposis coli, <3 months after participation in other clinical trials.
Other research projects, whereby radiation is used. Hemoglobin <8 mmol/l, Metal implants and claustrophobia, incompatible with CMR.
Congestive heart failure (NYHA functional score > I), atrial fibrillation or history of sustained ventricular tachycardia.
Stroke within 6 months prior to enrollment.
Microvascular complications, including:
diabetic nephropathy, proliferative retinopathy, symptomatic macrovascular complications and/or (autonomic) neuropathy, except for background diabetic retinopathy.
Leg ulcers, gangrene. Hyper sensibility to study medication.
Current use of TZD/fibrates Healthy volunteersHistory or current cardiovascular diseaseDyslipidemia, requiring pharmacological treatment according to the Dutch Cholesterol Consensus 1998
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL145 |
| NTR-old | NTR180 |
| Ander register | : N/A |
| ISRCTN | ISRCTN53177482 |